|
注册号: Registration number: |
ChiCTR2400093709 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-10 17:15:17 |
|
注册时间: Date of Registration: |
2024-12-10 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
在初诊未穿刺疑似前列腺癌患者中行有无PSMA PET/CT靶向穿刺的前列腺穿刺活检诊断前列腺癌的头对头、前瞻性、多中心、随机对照研究 |
|
Public title: |
Head-to-Head Comparison of Transrectal Ultrasound-Guided Prostate Biopsy With and Without PSMA-PET–Targeted Prostate Biopsy in Biopsy-Naïve Men with Suspected Prostate Cancer: A Prospective, Randomized, Multicenter Study |
|
注册题目简写: |
PSMA-PRECSION试验 |
|
English Acronym: |
PSMA-PRECSION Trial |
|
研究课题的正式科学名称: |
在初诊未穿刺疑似前列腺癌患者中行有无PSMA PET/CT靶向穿刺的前列腺穿刺活检诊断前列腺癌的头对头、前瞻性、多中心、随机对照研究 |
|
Scientific title: |
Head-to-Head Comparison of Transrectal Ultrasound-Guided Prostate Biopsy With and Without PSMA-PET–Targeted Prostate Biopsy in Biopsy-Naïve Men with Suspected Prostate Cancer: A Prospective, Randomized, Multicenter Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
焦健华 |
研究负责人: |
秦卫军 |
|
Applicant: |
Jiao Jianhua |
Study leader: |
Qin Weijun |
|
申请注册联系人电话: Applicant telephone: |
+86 187 0091 9857 |
研究负责人电话:
Study leader's |
+86 84775321 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1531769428@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
qinweij@fmmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市长乐西路127号 |
研究负责人通讯地址: |
陕西省西安市长乐西路127号 |
|
Applicant address: |
127 West Changle Road, Xi’an, Shaanxi, China |
Study leader's address: |
127 West Changle Road, Xi’an, Shaanxi, China |
|
申请注册联系人邮政编码: Applicant postcode: |
710032 |
研究负责人邮政编码: Study leader's postcode: |
710032 |
|
申请人所在单位: |
中国人民解放军空军军医大学西京医院 |
||
|
Applicant's institution: |
Xijing Hospital, Airforce Medical University, PLA |
||
|
研究负责人所在单位: |
中国人民解放军空军军医大学西京医院 |
||
|
Affiliation of the Leader: |
Xijing Hospital, Airforce Medical University, PLA |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY20212270-F-1号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军空军军医大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of The First Affiliated Hospital, Airforce Medical University, PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-30 00:00:00 | ||
|
伦理委员会联系人: |
贾艳艳 |
||
|
Contact Name of the ethic committee: |
Jia Yanyan |
||
|
伦理委员会联系地址: |
陕西省西安市长乐西路127号 |
||
|
Contact Address of the ethic committee: |
127 West Changle Road, Xi’an, Shaanxi, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 84771794 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
XJYYLLWYH@163.com |
|
研究实施负责(组长)单位: |
中国人民解放军空军军医大学西京医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xijing Hospital, Airforce Medical University, PLA |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省西安市长乐西路127号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
127 West Changle Road, Xi’an, Shaanxi, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金(82220108004;82404055) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China(No:82220108004; No: 82404055) |
||||||||||||||||||||||
|
研究疾病: |
前列腺癌 |
||||||||||||||||||||||
|
Target disease: |
Prostate Cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1、主要目的:比较前列腺穿刺活检加PSMA PET/CT靶向活检与单独行前传统前列腺穿刺活检相比在疑似前列腺癌患者中对临床显著性前列腺癌(csPCa, GG≥2)的诊断效能 2、次要目的:比较两种穿刺方法对非临床显著行前列腺癌(GG1)和高危前列腺癌(GG≥3)患者的诊断效能,并在联合组中比较传统前列腺穿刺和PSMA PET/CT靶向穿刺对前列腺爱的诊断诊断效能。分析可能改进的前列腺穿刺方法 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Main objective: To compare the diagnostic efficacy of prostate biopsy combined with PSMA PET/CT targeted biopsy and traditional prostate biopsy alone for clinically significant prostate cancer (csPCa, GG >= 2) in suspected prostate cancer patients 2. Secondary objective: To compare the diagnostic efficacy of two puncture methods for non clinically significant prostate cancer (GG1) and high-risk prostate cancer (GG >= 3) patients, and to compare the diagnostic efficacy of traditional prostate puncture and PSMA PET/CT targeted puncture for prostate cancer in the combination group. Analyze possible improved prostate puncture methods |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)既往前列腺穿刺活检诊断为前列腺癌; (2) PSMA PET/CT中PRIMARY 1分患者; (3)近两年内出现过其他恶性肿瘤的病史; (4)根据研究医师判断,可能出现严重并发症并影响实验正常进行 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Previous diagnosis of prostate cancer through prostate biopsy; (2) PSMA PET/CT patients with a PRIMAY score of 1; (3) History of other malignant tumors in the past two years; (4) According to the research physician's judgment, serious complications may occur and affect the normal conduct of the experiment |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-10-08 00:00:00至 To 2025-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-10-08 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由临床试验管理人员采用统计学软件产生随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random sequences generated by clinical trial management personnel using statistical software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
文章发表后,访问者需邮箱联系研究负责人或通讯作者1531769428@qq.com |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the publication of the article,visitors should contact the principal investigator orcorresponding author via email |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
eCRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
eCRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |